← Back to headlines
Biotech Firm Arcellx Acquired for $26 Million Amid Stock Underperformance and Competition
Biotech company Arcellx has been sold for $26 million, following a period of weak stock performance and increasing competition from rivals like Kelonia.
17 Feb, 18:07 — 17 Feb, 18:07
Sources
Showing 1 of 1 sources
Related Stories
Nvidia Nears $14 Billion Acquisition Deal for AI Startup Hugging Face
21m ago
US-Iran Strikes Trigger Oil Surge and Global Market Volatility
34m ago
Bessent Defends Economic Pressure Strategy Against Iran and Tariff Proposals
50m ago
Casablanca Airport Sets Daily Passenger Record Amid Summer Travel Surge
59m ago